Lilly’s Taltz® (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment...

Read More